Table 3: Differences between FMEDD, NO, ET-1, MDA, after SOD after glucose load.

GroupControl groupPrediabetes groupsNewly diagnosed type 2 diabetes group valueP value

Number of patients (M/F)33 (12/21)33 (12/21)43 (25/18)
FMEDDFasting 28.81a .001*
After glucose load 16.09 .001*
P value .001 .001 .001
NOFasting174.76 ± 67.25153.69 ± 61.67128.02 ± 52.9112.28a.002***
After glucose load153.63 ± 60.06138.13 ± 60.79117.90 ± 48.259.43a.009**
P value .001.0006 .001
ET-1Fasting1.44 ± 1.511.62 ± 1.291.93 ± 1.791.87a.392
After glucose load1.66 ± 1.541.54 ± 1.472.13 ± 1.862.17a.338
P value .001.3878.0046
MDAFasting5.41 ± 1.325.72 ± 1.185.76 ± 1.290.8.454
After glucose load6.03 ± 1.626.14 ± 1.646.31 ± 1.650.49a.783
P value .001.1938.0003
SODFasting169.24 ± 22.35143.94 ± 17.37118.51 ± 17.2663.73a .001*
After glucose load159.85 ± 22.57127.88 ± 14.24100.93 ± 17.3777.17a .001*
P value.0052.0011.0002

FMEDD: flow-mediated endothelium-dependent dilation; NO: nitric oxide; ET-1: endothelin-1; MDA: malondialdehyde; SOD: superoxide dismutase.
aUsing nonparametric analysis method.
*Significant among the 3 groups.
**Significantly different in newly diagnosed type 2 diabetes and control groups.
***Significantly different in newly diagnosed type 2 diabetes and control groups, prediabetes groups, and newly diagnosed type 2 diabetes group.